Floatz logo

Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain

Non-Small Cell Lung Carcinoma

Explore 1,128 assets in Non-Small Cell Lung Carcinoma →
Floatz Rating
CC43/100
Confidence
Indicative
v0.2
Sponsor
AstraZeneca
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04612751CT.gov
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
—Active Not Recruiting———
NCT03819465CT.gov
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Non-Small Cell Lung Carcinoma

AssetSponsorPhaseRating
Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain (this asset)AstraZenecaP1CC · 43
NecitumumabJonsson Comprehensive Cancer CenterP3BBB
GlumetinibShanghai JMT-Bio Inc.P3BBB
VeliparibAbbVieP3BBB
d-0316Betta Pharmaceuticals Co., Ltd.P2/3BBB
IcotinibThe First Affiliated Hospital of Guangzhou Medical UniversityP4BBB
ZoledronateChia Tai Tianqing Pharmaceutical Group Co., Ltd.P4BBB
OnartuzumabHoffmann-La RocheP3BBB
AvitinibHangzhou ACEA Pharmaceutical Research Co., Ltd.P3BBB

+42 more in the Non-Small Cell Lung Carcinoma cohort

Other indications for Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain

IndicationSponsorPhaseRating
Cancer—P2CCC · 50
Neoplasm—P1CC · 43
Renal Cell Carcinoma—P1CC · 41

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain in Non-Small Cell Lung Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g1-134-cysteine228-valine242-phenylalanine243-glutamic-acid339-serine362-cysteine374-tryptophan-anti-human-cytotoxic-t-lymphocyte-associated-protein-4-human-monoclonal-medi5752-gamma1-chain-disulfide-with-122-cysteine212-valine-human-monoclonal-medi5752-lambda-chain-234-231237-234362-354-trisdisulfide-with-immunoglobulin-g1-239-phenylalanine240-glutamic-acid336-serine354-cysteine371-serine373-alanine412-valine-anti-human-programmed-cell-death-protein-1-human-mus-musculus-monoclonal-medi5752-gamma1-chain-disulfide-with-human-mus-musculus-monoclonal-medi5752-kappa-chain-non-small-cell-lung-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →